Skip to main content

MEK-NF-201 A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients with Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) that are Progressing or Causing Significant Morbidity

NCT03962543

A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients with Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) that are Progressing or Causing Significant Morbidity

Associated Conditions

Neurofibromatosis

Principal Investigator

Sponsor

SpringWorks Therapeutics

This research is conducted to study an investigational drug referred to as PD-0325901 (also known as mirdametinib) that has not been approved by the US Food and Drug Administration (FDA) or any other Regulatory Authority for the treatment of Neurofibromatosis. The purpose of this research study is to investigate the safety, tolerability and how well PD-0325901 works in participants with Neurofibromatosis.

This study is currently enrolling.